CD206 Antibody, anti-human, REAfinity™
Synonyms: MMR
RECOMBINANT EXTENDED VALIDATION
Bioz Star96/100 Bioz rating
2 Citations
Clone:
REA1207 | DCN228
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD206 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
PE-Vio 670
Vio Bright B515
Vio Bright R720
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-123-160, 130-123-169
Description:
Human peripheral blood mononuclear cells (PBMCs) were stimulated with 2 µg/mL GM-CSF and 50 ng/mL IL-4 for 3 days. Cells were then stained with CD206 antibodies or with the corresponding REA Control (S) antibodies (left image), as well as with CD11c antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates

Application imageView details view details

Application imageView details view details
Extended validation for CD206 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1207
DCN228
high
19.2
low
15-2
low

Cells were incubated with an excess of purified unconjugated CD206 (REA1207) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD206 (REA1207). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD206 Antibody, anti-human, REAfinity™
Overview

Clone REA1207 recognizes the human CD206 antigen, also known as Mannose receptor (MR) or macrophage MR, which is a 162–175 kDa type I membrane protein. It contains an N-terminal cystein-rich domain and eight C-type lectin-like domains (CTLDs), beside a transmembrane and a cytoplasmic domain. CD206 is expressed by macrophages, dendritic cells, and subsets of endothelial cells, but not on monocytes. The MR recognizes multiple mainly microbial carbohydrates with mannose, fucose, or N-acetyl glucosamine residues. The MR mediates endocytosis and phagocytosis, linked to antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity.

Additional information: Clone REA1207 displays negligible binding to Fc receptors.

Alternative names

MMR

Detailed product information

Technical specifications

Clone
REA1207
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD206
Molecular mass of antigen [kDa]
164
Distribution of antigen
endothelial cells, dendritic cells, macrophages, plasma cells, placenta
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD206 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?